Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

In a special edition of Rootwork on KPFK, Thandi Chimurenga of Black Liberation Media sat down with Kali Akuno of Cooperation Jackson to explore bold strategies for grassroots survival and resistance.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

Breast cancer remains the most common cancer among women globally, and Germany stands at the forefront of offering advanced and effective treatment options. Through a combination of high medical ...